Current Fungal Infection Reports

, Volume 4, Issue 4, pp 197–199 | Cite as

Fluconazole Therapy for Cryptococcal Meningitis: Are Options Available Where It Is Needed Most—Africa?

Clinical Trial Report

References

  1. 1.
    Park BJ, Wannemuehler KA, Marston BA, et al.: Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009, 23:525–530.CrossRefPubMedGoogle Scholar
  2. 2.
    Lawn SD, Harries AD, Anglaret X, et al.: Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008, 22:1897–1908.CrossRefPubMedGoogle Scholar
  3. 3.
    Bicanic T, Meintjes G, Wood R, et al.: Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis 2007, 45:76–80.CrossRefPubMedGoogle Scholar
  4. 4.
    Chang LW, Phipps WT, Kennedy GE, Rutherford GW: Antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV. Cochrane Database Syst Rev 2005, (3):CD004773.Google Scholar
  5. 5.
    Apisarnthanarak A, Mundy LM: The impact of primary prophylaxis for cryptococcosis on fluconazole resistance in Candida species. J Acquir Immune Defic Syndr 2008, 47:644–645.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC (outside the USA) 2010

Authors and Affiliations

  1. 1.National Center for Emerging and Zoonotic Infectious DiseasesCenters for Disease Control and PreventionAtlantaUSA

Personalised recommendations